Literature DB >> 19478440

Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL.

Thomas S Walter1, Changzhen Liu, Peng Huang, Shiqian Zhang, Lucy R Wedderburn, Bin Gao, Raymond J Owens, David I Stuart, Peifu Tang, Jingshan Ren.   

Abstract

The interaction between the TNF-family molecule receptor activator of NF-kappaB ligand (RANKL) and its receptor RANK induces osteoclast formation, activation and survival in the process of bone remodelling. RANKL-RANK also plays critical roles in T-cell/dendritic cell communication and lymph-node formation and in a variety of pathologic conditions such as tumour-cell migration and bone metastasis. Both the ectodomain of mouse RANKL and the extracellular domain of mouse RANK have been cloned, expressed and purified. Crystals of RANK alone and of RANK in complex with RANKL have been obtained that are suitable for structure determination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478440      PMCID: PMC2688419          DOI: 10.1107/S1744309109015735

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  21 in total

1.  Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.

Authors:  J Mongkolsapaya; J M Grimes; N Chen; X N Xu; D I Stuart; E Y Jones; G R Screaton
Journal:  Nat Struct Biol       Date:  1999-11

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

3.  Benefits of automated crystallization plate tracking, imaging, and analysis.

Authors:  Christopher J Mayo; Jonathan M Diprose; Thomas S Walter; Ian M Berry; Julie Wilson; Ray J Owens; E Yvonne Jones; Karl Harlos; David I Stuart; Robert M Esnouf
Journal:  Structure       Date:  2005-02       Impact factor: 5.006

Review 4.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

5.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.

Authors:  S G Hymowitz; H W Christinger; G Fuh; M Ultsch; M O'Connell; R F Kelley; A Ashkenazi; A M de Vos
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

6.  Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.

Authors:  Shuichiro Ito; Kenji Wakabayashi; Osamu Ubukata; Shinko Hayashi; Fumihiko Okada; Tadashi Hata
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

Review 7.  RANK-L and RANK: T cells, bone loss, and mammalian evolution.

Authors:  Lars E Theill; William J Boyle; Josef M Penninger
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

8.  Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.

Authors:  J Lam; C A Nelson; F P Ross; S L Teitelbaum; D H Fremont
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Koichi Matsuo; Hiroshi Suzuki; Tomohiko Suzuki; Kojiro Sato; Taeko Yokochi; Hiromi Oda; Kozo Nakamura; Nobutaka Ida; Erwin F Wagner; Tadatsugu Taniguchi
Journal:  Nature       Date:  2002-04-18       Impact factor: 49.962

Review 10.  All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction.

Authors:  Jee Y Chung; Young Chul Park; Hong Ye; Hao Wu
Journal:  J Cell Sci       Date:  2002-02-15       Impact factor: 5.285

View more
  2 in total

1.  Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis.

Authors:  Dane Huang; Chao Zhao; Ruyue Li; Bingyi Chen; Yuting Zhang; Zhejun Sun; Junkang Wei; Huihao Zhou; Qiong Gu; Jun Xu
Journal:  Nat Commun       Date:  2022-09-12       Impact factor: 17.694

2.  A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis.

Authors:  Changzhen Liu; Yunfeng Zhao; Wen He; Wei Wang; Yuan Chen; Shiqian Zhang; Yijing Ma; Jin Gohda; Takaomi Ishida; Thomas S Walter; Raymond J Owens; David I Stuart; Jingshan Ren; Bin Gao
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.